Skip to main content
. 2022 Apr 5;44(4):568–577. doi: 10.1097/FTD.0000000000000984

TABLE 2.

Validation Results of DBS Including Accuracy and Imprecision Within-Day and Between-Day

Compound QC Concentrations (μg/L) Within-Day (n = 6) Between-Day (n = 12)
Actual Measured* Accuracy (Bias %) Imprecision (CV%) Accuracy (Bias %) Imprecision (CV%)
Amlodipine QC low 21.01 22.1 5.5 3.6 5.3 6.5
QC medium 210.1 231.1 7.1 8.7 10.0 13.1
QC high 300.1 315.4 −6.2 12.9 5.1 14.4
Barnidipine QC low 8.2 7.9 −14.4 5.8 −2.6 9.5
QC medium 79.0 92.4 13.6 6.0 17.1 6.0
QC high 114.3 129.8 13.0 2.3 13.5 7.0
Bumetanide QC low 15.5 15.4 −14.4 7.5 −0.6 8.9
QC medium 154.7 164.5 13.6 2.6 6.3 5.0
QC high 221.1 328.4 13.0 2.7 48.6 7.4
Candesartan (−) QC low 122.7 86.8 −30.9 17.5 −29.2 21.3
QC medium 563.3 553.6 −7.9 6.5 −1.7 9.2
QC high 804.7 770.4 −17.0 11.1 −4.3 11.1
Canrenone QC low 77.8 72.6 −18.7 10.0 −6.6 13.9
QC medium 777.5 835.0 14.2 2.4 7.4 4.9
QC high 1110.7 1189.7 12.6 2.8 7.1 6.0
Chlorthalidone (−) QC low 41.5 34.0 −9.2 14.3 −18.2 18.3
QC medium 207.7 202.8 7.6 10.8 −2.3 9.8
QC high 296.6 294.3 7.4 11.1 −0.8 13.3
Doxazosin QC low 67.1 60.6 −9.0 2.7 −9.7 5.4
QC medium 671.1 681.3 3.9 3.0 1.5 5.1
QC high 958.7 960.3 3.8 2.0 0.2 4.1
Enalapril QC low 4.4 5.1 12.6 6.2 16.5 6.8
QC medium 30.6 34.2 14.2 2.3 11.8 14.5
QC high 43.7 49.1 15.2 9.1 12.2 5.7
Enalaprilat QC low 3.2 3.5 16.3 8.0 9.8 11.7
QC medium 22.5 28.4 19.0 3.6 26.2 11.2
QC high 32.2 40.4 17.9 13.7 25.7 14.1
Hydrochlorothiazide (−) QC low 85.7 75.2 −2.6 12.4 −12.3 24.6
QC medium 428.4 380.0 14.9 13.6 −11.3 10.4
QC high 612.0 590.5 15.7 8.8 −3.5 16.0
Irbesartan QC low 72.8 76.2 7.4 3.4 4.7 4.2
QC medium 728.0 744.1 8.7 8.9 2.2 6.9
QC high 1040.0 1067.6 10.1 7.2 2.7 9.4
Losartan QC low 12.1 12.2 2.2 4.2 1.7 7.0
QC medium 84.4 95.7 9.4 1.9 13.5 7.5
QC high 120.5 135.4 12.5 8.7 12.4 5.4
Losartan-carboxylic acid QC low 24.4 22.2 −7.8 8.4 −8.9 8.5
QC medium 171.0 169.5 −10.1 1.9 −0.9 10.0
QC high 244.3 239.5 −8.3 10.2 −2.0 7.7
Metoprolol QC low 15.3 15.4 4.2 4.2 0.4 5.0
QC medium 153.4 155.0 7.2 2.6 1.1 6.5
QC high 219.2 220.2 3.2 3.7 0.5 6.2
Nifedipine QC low 19.9 27.2 14.1 9.8 36.7 19.2
QC medium 199.1 335.3 −9.2 3.4 68.3 40.8
QC high 284.5 340.7 −28.0 4.4 19.8 27.2
Perindopril QC low 7.1 4.6 −4.7 5.0 −35.7 27.3
QC medium 71.4 42.5 −2.7 10.3 −40.5 30.6
QC high 102.0 61.0 −0.7 9.8 −40.2 39.0
Perindoprilat QC low 5.8 6.4 0.6 7.0 9.0 12.5
QC medium 58.3 67.5 10.2 11.7 15.8 3.7
QC high 83.3 97.1 14.7 9.7 16.6 6.7
Spironolactone QC low 19.9 18.3 −14.2 7.5 −7.7 7.9
QC medium 198.8 207.2 8.9 3.2 4.2 7.3
QC high 284.0 291.3 8.0 2.2 2.6 6.3
Telmisartan (−) QC low 280.5 266.2 16.9 18.2 −5.1 6.8
QC medium 1402.2 1431.5 10.4 12.0 2.1 5.2
QC high 2003.2 2062.8 15.0 11.5 3.0 13.1
Valsartan QC low 140.17 153.2 19.2 5.9 9.3 8.8
QC medium 1401.7 1476.4 15.8 12.5 5.3 8.7
QC high 2002.4 2132.0 18.1 12.8 6.5 12.7
*

Each value represents the mean of duplicate samples measured.

Value does not meet the requirement of <15%.

Value does not meet the requirement of <20%.

NA, not available; CV, coefficient of variation.